Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $25 million public offering of 4,166,667 common shares of Millendo Therapeutics, Inc. Millendo’s common stock is listed on the Nasdaq Global Select Market under the symbol “MLND.”

Millendo is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause.

The Davis Polk capital markets team included partner Deanna L. Kirkpatrick and associate Angela Park. Partner David R. Bauer and associate Yifu Chen provided intellectual property and technology advice. Counsel Ethan R. Goldman and associate Summer Xia provided tax advice. Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and London offices.

Copy link to share post